Skip to main content

Table 4 Effect of rs12979860 genotype on percentage sustained viral response for boceprevir and telaprevir treatment regimes

From: Pharmacogenomics of hepatitis C infections: personalizing therapy

Treatment

Genotype (%SVR)

 

CC

CT

TT

SPRINT-2 (n = 653)

   

PegIFN/R

78

28

27

BOC/RGT

82

65

55

BOC/PR48

80

71

59

No HCV at 8 weeks

89

52

ADVANCE (n = 454)

   

PegIFN/R

64

25

23

T8 24/48

84

57

59

T12 24/48

90

71

73

No HCV at 4 and 12 weeks

72

52

  1. %SVR, percentage sustained viral response. Data from SPRINT-2 (boceprevir, BOC) [49] and ADVANCE (telaprevir, T) clinical trials [50]. SPRINT-2 regime: PegIFN/R for 48 weeks. BOC/RGT: PegIFN/R for 4 weeks, then 24 weeks; BOC and PegIFN/R if HCV undetectable, 44 weeks if not. BOC/PR48: PegIFN/R for 4 weeks, then 44 weeks BOC and PegIFN/R. No hepatitis C virus (HCV) based on detection at 8 weeks. ADVANCE regime: PegIFN/R for 48 weeks. T8 24/48: telaprevir for 8 weeks, PegIFN/R for 24 or 48 weeks, dependent on HCV at 4 and 12 weeks. T12 24/48: telaprevir for 12 weeks, PegIFN/R for 24/48 weeks. No HCV based on detection at 4 and 12 weeks of treatment.
Back to article page

Genome Medicine

ISSN: 1756-994X

Contact us